ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
3.530
-0.110 (-3.02%)
Nov 6, 2024, 4:00 PM EST - Market closed

Company Description

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.

The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.

coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.

In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ImmuCell Corporation
ImmuCell logo
Country United States
Founded 1982
IPO Date Apr 30, 1987
Industry Biotechnology
Sector Healthcare
Employees 79
CEO Michael Brigham

Contact Details

Address:
56 Evergreen Drive
Portland, Maine 04103
United States
Phone 207 878 2770
Website immucell.com

Stock Details

Ticker Symbol ICCC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000811641
CUSIP Number 452525306
ISIN Number US4525253062
Employer ID 01-0382980
SIC Code 2835

Key Executives

Name Position
Michael F. Brigham President, Chief Executive Officer, Principal Financial Officer, Treasurer, Secretary and Director
Bobbi Jo Brockmann Vice President of Sales and Marketing and Director
Elizabeth L. Williams Vice President of Manufacturing Operations
Elizabeth S. Toothaker Director of Finance and Administration and Controller
A. Gustavo Scaffa Senior Director of Quality
John W. Zinckgraf Director of Product Development

Latest SEC Filings

Date Type Title
Oct 8, 2024 8-K Current Report
Sep 24, 2024 8-K Current Report
Sep 17, 2024 SCHEDULE 13D/A Filing
Aug 27, 2024 SC 13D General statement of acquisition of beneficial ownership
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jul 9, 2024 8-K Current Report
Jun 14, 2024 8-K Current Report
Jun 14, 2024 8-K Current Report
Jun 6, 2024 8-K Current Report